Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma
Lenvatinib, an oral small-molecule multiple tyrosine kinase inhibitor (TKI), has been approved for first-line therapy for unresectable hepatocellular carcinoma (HCC). Proteinuria is one of the most common adverse events associated with lenvatinib treatment. We reported a 67-year-old Thai female was...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2022-01-01
|
| Series: | Case Reports in Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2022/5101856 |
| _version_ | 1797994917215076352 |
|---|---|
| author | Thaninee Prasoppokakorn Kessarin Thanapirom Sombat Treeprasertsuk |
| author_facet | Thaninee Prasoppokakorn Kessarin Thanapirom Sombat Treeprasertsuk |
| author_sort | Thaninee Prasoppokakorn |
| collection | DOAJ |
| description | Lenvatinib, an oral small-molecule multiple tyrosine kinase inhibitor (TKI), has been approved for first-line therapy for unresectable hepatocellular carcinoma (HCC). Proteinuria is one of the most common adverse events associated with lenvatinib treatment. We reported a 67-year-old Thai female was diagnosed with NASH cirrhosis and HCC BCLC B with TACE refractoriness. She received 8 mg of lenvatinib for 2 weeks and began to experience worsening hypertension, bilateral pleural effusion, pedal edema, hypoalbuminemia, hypercholesterolemia, and proteinuria. After exclusion of all possible causes, lenvatinib-induced nephrotic syndrome (NS) was diagnosed. One week after discontinuing the drug, her symptoms gradually improved. To date, there have been only a handful of reported cases of lenvatinib-induced nephrotoxicity. We report herein the case of lenvatinib-induced NS in a cirrhotic patient with HCC with resolution of symptoms in a short period after drug discontinuation. In addition, we reviewed all reported cases of lenvatinib-induced nephrotoxicity. |
| first_indexed | 2024-04-11T09:53:18Z |
| format | Article |
| id | doaj.art-a7740eb5c63e44889e0e3148b988785d |
| institution | Directory Open Access Journal |
| issn | 2090-6595 |
| language | English |
| last_indexed | 2024-04-11T09:53:18Z |
| publishDate | 2022-01-01 |
| publisher | Hindawi Limited |
| record_format | Article |
| series | Case Reports in Hepatology |
| spelling | doaj.art-a7740eb5c63e44889e0e3148b988785d2022-12-22T04:30:44ZengHindawi LimitedCase Reports in Hepatology2090-65952022-01-01202210.1155/2022/5101856Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular CarcinomaThaninee Prasoppokakorn0Kessarin Thanapirom1Sombat Treeprasertsuk2Division of GastroenterologyDivision of GastroenterologyDivision of GastroenterologyLenvatinib, an oral small-molecule multiple tyrosine kinase inhibitor (TKI), has been approved for first-line therapy for unresectable hepatocellular carcinoma (HCC). Proteinuria is one of the most common adverse events associated with lenvatinib treatment. We reported a 67-year-old Thai female was diagnosed with NASH cirrhosis and HCC BCLC B with TACE refractoriness. She received 8 mg of lenvatinib for 2 weeks and began to experience worsening hypertension, bilateral pleural effusion, pedal edema, hypoalbuminemia, hypercholesterolemia, and proteinuria. After exclusion of all possible causes, lenvatinib-induced nephrotic syndrome (NS) was diagnosed. One week after discontinuing the drug, her symptoms gradually improved. To date, there have been only a handful of reported cases of lenvatinib-induced nephrotoxicity. We report herein the case of lenvatinib-induced NS in a cirrhotic patient with HCC with resolution of symptoms in a short period after drug discontinuation. In addition, we reviewed all reported cases of lenvatinib-induced nephrotoxicity.http://dx.doi.org/10.1155/2022/5101856 |
| spellingShingle | Thaninee Prasoppokakorn Kessarin Thanapirom Sombat Treeprasertsuk Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma Case Reports in Hepatology |
| title | Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma |
| title_full | Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma |
| title_fullStr | Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma |
| title_full_unstemmed | Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma |
| title_short | Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma |
| title_sort | nephrotic syndrome induced by lenvatinib treatment for hepatocellular carcinoma |
| url | http://dx.doi.org/10.1155/2022/5101856 |
| work_keys_str_mv | AT thanineeprasoppokakorn nephroticsyndromeinducedbylenvatinibtreatmentforhepatocellularcarcinoma AT kessarinthanapirom nephroticsyndromeinducedbylenvatinibtreatmentforhepatocellularcarcinoma AT sombattreeprasertsuk nephroticsyndromeinducedbylenvatinibtreatmentforhepatocellularcarcinoma |